These include age, gender, tumor level, response to radiation and chemotherapy, IDH1 mutation status, MGMT promoter methylation position, 1p/19q teamed up-deletion situation, TERT expression and TERT mutant status, as well as ATRX mutation status, as described in Additional file 14: Table S6. This evidence concerns the gene IDH1 and neoplasm.